Drug industry lawyers are trying to figure out how the administration will proceed with plans to base Medicare reimbursement on the cheapest drug prices among develop countries after the release of a most-favored-nation executive order over the weekend, and they’re reviewing recent court cases and the handling of past Medicare innovation center demonstrations as they prepare to challenge the president’s signature drug pricing policy. The big news is that the order adds Part D to the president’s international reference pricing...